Product Name | NDP - MSH, 5 - TAMRA - labeled5 - TMR - SYS - Nle - EHfRWGKPV - NH2 |
Size | 1 mg |
Catalog # | AS-60564-1 |
US$ | $351 |
Purity | % Peak Area By HPLC ≥ 95% |
This NDP-MSH peptide is fluorescently (5-TAMRA)-labeled on the N-terminus. Abs/Em=544/572 nm. NDP-MSH is a synthetic analog of alpha-Melanotropin (α-MSH, α-melanocyte-stimulating hormone) in which Asp4 has been replaced with Norleucine and L-Phe with the D-isomer of Phe [Nle4D-Phe7] (NDP). NDP-MSH is a more potent in increasing pigmentation and decreasing UV damage in fair-skinned Caucasian volunteers. | |
Detailed Information | Material Safety Data Sheets (MSDS) |
Storage | -20°C |
References | Sawyer, TK. et al. Proc Natl Acad Sci 77, 5754 (1980)Barnetson, RS. et al. J Invest Dermatol 126, 1869 (2006), doi: 10.1038/sj.jid.5700317 |
Molecular Weight | 2017.3 |
5-TMR-SYS-Nle-EHfRWGKPV-NH2 | |
Sequence(Three-Letter Code) | 5 - TMR - Ser - Tyr - Ser - Nle - Glu - His - D - Phe - Arg - Trp - Gly - Lys - Pro - Val - NH2 |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
)懂得一些道理或知识.
让世界充满爱不仅是付出,还可以是回报,回报你所关爱的人.
我记得有首歌曲,它的意思是爸爸妈妈辛苦了一天,回到家,帮他们拿拖鞋,帮他们倒杯茶,这是感
恩.老师批改作业累了,可以给他们捶捶背,当学习获得了一定的成功,老师会感到欣慰,这是感恩.当
同学遭遇困难时,你可以去用尽全力地安慰帮助他(她),使他(她)能够解决困难,克服困难,变得快
乐.这也是感恩.
B、是重要的储能物质,磷脂为构成生物膜的重要成分,固醇为动物细胞膜的构成物质及形成激素等,B错误;
C、蛋白质是细胞代谢的主要结构物质,糖类是细胞代谢的主要能源物质C错误;
D、ATP的结构简式是 A-P~P~P,其中A代表腺苷,腺苷是构成ATP的重要部分,D正确.
故选:D.
第一类激素作用在靶细胞表面,并不进入细胞内部,而是与细胞膜表面特异的受体结合.这种结合使腺苷酸环化酶激活产生cAMP(一种第二信使),cAMP再去激活细胞内的一些特定系列的酶,从而引起各种生理效应.这是由E.W.Sutherland于1965年提出来的第二信使假说
第二类激素由于是脂溶性的小分子.能直接进入靶细胞,与靶细胞的细胞质中的受体分子结合成"激素-受体复合物",在一定条件下穿过核膜进入核内,与染色质上的一种酸性蛋白质相互作用,促进DNA样板转录相应的mRNA.
mRNA扩散出核膜进入细胞质,导致某种蛋白质(酶)的合成,从而引起这种激素的生理效应.
http://care.diabetesjournals.org/cgi/content/abstract/31/8/1479
OBJECTIVE—Hyperglycemiaisariskfactorformicrovascularcomplicationsandmayincreasetheriskofcardiovasculardiseaseinpatientswithtype2diabetes.ThisstudytestedtheLDLcholesterol–loweringagentcolesevelamHCl(colesevelam)asapotentialnoveltreatmentforimprovingglycemiccontrolinpatientswithtype2diabetesonsulfonylurea-basedtherapy.
RESEARCHDESIGNANDMETHODS—A26-week,randomized,double-blind,placebo-controlled,parallel-group,multicenterstudywascarriedoutbetweenAugust2004andAugust2006toevaluatetheefficacyandsafetyofcolesevelamforreducingA1Cinadultswithtype2diabeteswhoseglycemiccontrolwasinadequate(A1C7.5–9.5%)withexistingsulfonylureamonotherapyorsulfonylureaincombinationwithadditionaloralanti-diabetesagents.Intotal,461patientswererandomized(230givencolesevelam3.75g/dayand231givenplacebo).Theprimaryefficacymeasurementwasmeanplacebo-correctedchangeinA1Cfrombaselinetoweek26intheintent-to-treatpopulation(lastobservationcarriedforward).
RESULTS—Theleastsquares(LS)meanchangeinA1Cfrombaselinetoweek26was–0.32%inthecolesevelamgroupand+0.23%intheplacebogroup,resultinginatreatmentdifferenceof–0.54%(P<0.001).TheLSmeanpercentchangeinLDLcholesterolfrombaselinetoweek26was–16.1%inthecolesevelamgroupand+0.6%intheplacebogroup,resultinginatreatmentdifferenceof–16.7%(P<0.001).FurThermore,significantreductionsinfastingplasmaglucose,fructosamine,totalcholesterol,non–HDLcholesterol,andapolipoproteinBweredemonstratedinthecolesevelamrelativetoplacebogroupatweek26.
CONCLUSIONS—ColesevelamimprovedglycemiccontrolandreducedLDLcholesterollevelsinpatientswithtype2diabetesreceivingsulfonylurea-basedtherapy.
暂无品牌问答